Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Thurin NH, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rébillard X, Soulié M, de Pouvourville G, Capone C, Bazil ML, Messaoudi F, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Thurin NH, et al. Among authors: capone c. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1139-1145. doi: 10.1080/17512433.2022.2115356. Epub 2022 Aug 25. Expert Rev Clin Pharmacol. 2022. PMID: 35984212
Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database.
Thurin NH, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, Roumiguié M, Le Moulec S, Capone C, Pierrès M, Lamarque S, Jové J, Bignon E, Droz-Perroteau C, Moore N, Blin P. Thurin NH, et al. Among authors: capone c. Cancer Epidemiol. 2020 Dec;69:101833. doi: 10.1016/j.canep.2020.101833. Epub 2020 Oct 14. Cancer Epidemiol. 2020. PMID: 33068878 Free article.
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA. Chowdhury S, et al. Among authors: capone c. Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19. Adv Ther. 2022. PMID: 34797506 Free PMC article. Clinical Trial.
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, Lopez-Casas PP, Jambrina A, Capone C, Vanden Broecke AM, Trevisan M, Van Sanden S, Jürgens A, Herrera-Imbroda B, Castro E. Olmos D, et al. Among authors: capone c. Ann Oncol. 2024 May;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011. Epub 2024 Feb 27. Ann Oncol. 2024. PMID: 38417742 Free article.
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.
De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, Verzoni E. De Santis M, et al. Among authors: capone c. Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958846 Free PMC article. Review.
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
Roubaud G, Attard G, Boegemann M, Olmos D, Trevisan M, Antoni L, Pascoe K, Capone C, Van Sanden S, Hashim M, Palmer S, Chi K. Roubaud G, et al. Among authors: capone c. Eur J Cancer. 2024 Sep;209:114183. doi: 10.1016/j.ejca.2024.114183. Epub 2024 Jun 17. Eur J Cancer. 2024. PMID: 39111209 Clinical Trial.
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.
Eaton E, Capone C, Gully BJ, Brown ZE, Monnig M, Worden MS, Swift RM, Haass-Koffler CL. Eaton E, et al. Among authors: capone c. Contemp Clin Trials Commun. 2024 Jul 20;41:101333. doi: 10.1016/j.conctc.2024.101333. eCollection 2024 Oct. Contemp Clin Trials Commun. 2024. PMID: 39262902 Free PMC article.
Characterizing Long COVID in Children and Adolescents.
Gross RS, Thaweethai T, Kleinman LC, Snowden JN, Rosenzweig EB, Milner JD, Tantisira KG, Rhee KE, Jernigan TL, Kinser PA, Salisbury AL, Warburton D, Mohandas S, Wood JC, Newburger JW, Truong DT, Flaherman VJ, Metz TD, Karlson EW, Chibnik LB, Pant DB, Krishnamoorthy A, Gallagher R, Lamendola-Essel MF, Hasson DC, Katz SD, Yin S, Dreyer BP, Carmilani M, Coombs K, Fitzgerald ML, Güthe N, Hornig M, Letts RJ, Peddie AK, Taylor BD, Balaraman V, Bogie A, Bukulmez H, Dozor AJ, Eckrich D, Elliott AJ, Evans DN, Farkas JS, Faustino EVS, Fischer L, Gaur S, Harahsheh AS, Hasan UN, Hsia DS, Huerta-Montañez G, Hummel KD, Kadish MP, Kaelber DC, Krishnan S, Kosut JS, Larrabee J, Lim PPC, Michelow IC, Oliveira CR, Raissy H, Rosario-Pabon Z, Ross JL, Sato AI, Stevenson MD, Talavera-Barber MM, Teufel RJ, Weakley KE, Zimmerman E, Bind MC, Chan J, Guan Z, Morse RE, Reeder HT, Akshoomoff N, Aschner JL, Bhattacharjee R, Cottrell LA, Cowan K, D'Sa VA, Fiks AG, Gennaro ML, Irby K, Khare M, Guttierrez JL, McCulloh RJ, Narang S, Ness-Cochinwala M, Nolan S, Palumbo P, Ryu J, Salazar JC, Selvarangan R, Stein CR, Werzberger A, Zempsky WT, Aupperle R, Baker FC, Banich MT, Barch DM, Baskin-Sommers A, Bjork JM, Boo… See abstract for full author list ➔ Gross RS, et al. JAMA. 2024 Aug 21;332(14):1174-88. doi: 10.1001/jama.2024.12747. Online ahead of print. JAMA. 2024. PMID: 39196964 Free article.
171 results